Swiss National Bank raised its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,443,332 shares of the medical research company’s stock after acquiring an additional 43,600 shares during the quarter. Swiss National Bank owned 0.37% of Thermo Fisher Scientific worth $251,818,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in TMO. Waldron LP lifted its stake in Thermo Fisher Scientific by 48.1% in the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock valued at $661,000 after buying an additional 1,447 shares during the last quarter. Empire Life Investments Inc. raised its stake in shares of Thermo Fisher Scientific by 132.0% during the first quarter. Empire Life Investments Inc. now owns 52,504 shares of the medical research company’s stock valued at $7,861,000 after purchasing an additional 29,875 shares in the last quarter. US Bancorp DE raised its stake in shares of Thermo Fisher Scientific by 2.2% during the first quarter. US Bancorp DE now owns 220,270 shares of the medical research company’s stock valued at $33,834,000 after purchasing an additional 4,747 shares in the last quarter. AT Bancorp raised its stake in shares of Thermo Fisher Scientific by 31.1% during the first quarter. AT Bancorp now owns 27,988 shares of the medical research company’s stock valued at $4,299,000 after purchasing an additional 6,647 shares in the last quarter. Finally, Maple Capital Management Inc. raised its stake in shares of Thermo Fisher Scientific by 26.9% during the first quarter. Maple Capital Management Inc. now owns 2,137 shares of the medical research company’s stock valued at $328,000 after purchasing an additional 453 shares in the last quarter. 83.32% of the stock is owned by institutional investors and hedge funds.
In other news, Director C Martin Harris sold 360 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the sale, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. Insiders have sold 52,738 shares of company stock valued at $9,302,112 over the last quarter. Company insiders own 0.49% of the company’s stock.
Several brokerages have commented on TMO. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Leerink Swann lifted their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Cowen and Company reiterated an “outperform” rating and set a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Barclays PLC reiterated an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $203.64.
Shares of Thermo Fisher Scientific Inc (TMO) opened at 191.28 on Tuesday. The company has a market capitalization of $74.62 billion, a PE ratio of 33.32 and a beta of 1.05. The firm has a 50-day moving average price of $189.61 and a 200-day moving average price of $175.55. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $194.30.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same period last year, the business earned $2.03 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. On average, equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/swiss-national-bank-increases-holdings-in-thermo-fisher-scientific-inc-tmo/1698492.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with our FREE daily email newsletter.